Combined use of biomarkers for detection of ovarian cancer in high-risk women.
The aim of this study was to examine the negative predictive value for a panel of serum markers in women at high risk for developing ovarian cancer. A total of 201 serum samples were collected and analyzed from 102 women at "high risk" for ovarian cancer: 26 with primary ovarian cancer, 31 with recurrent ovarian cancer, 28 with benign gynecologic diseases, and 14 with other cancers. Samples were tested for cancer antigen (CA) 125 II, CA19-9, CA72-4, CA15-3, and macrophage colony-stimulating factor, OVX1, and the marker values were further used as input to be evaluated by a previously trained artificial neural network (ANN). CA125 alone identified 72% of the primary ovarian cancers at a specificity of 95%. If either CA125 or CA72-4 were elevated, sensitivity rose to 80%. Adding macrophage colony-stimulating factor-improved sensitivity to 84% and when CA15-3 was included, a sensitivity of 88% was achieved. Specificity of the four marker panel was, however, reduced to 82.5%. By contrast, at the same sensitivity of 88%, the ANN exhibited a much higher specificity at 92.5% (p = 0.0105). Our data suggest that the combined use of multiple biomarkers improve sensitivity in women at high risk for ovarian cancer. In contrast to the simple "or" combination rule, the ANN was able to achieve a higher sensitivity without significant loss in specificity.
Donach
Martin
M
Istituto Oncologico Veneto IRCCS, Padua, Italy.
Yu
Yinhua
Y
Artioli
Grazia
G
Banna
Giuseppe
G
Feng
Weiwei
W
Bast
Robert C
RC
Zhang
Zhen
Z
Nicoletto
Maria O
MO
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015295:Antigens, Tumor-Associated, Carbohydrate / Q000097:blood; D019313:BRCA1 Protein / Q000097:blood; D024682:BRCA2 Protein / Q000097:blood; D014408:Biomarkers, Tumor / Q000097:blood*; D018394:CA-125 Antigen / Q000097:blood; D018395:CA-19-9 Antigen / Q000097:blood; D005260:Female; D006023:Glycoproteins / Q000097:blood; D006801:Humans; D016173:Macrophage Colony-Stimulating Factor / Q000097:blood; D008875:Middle Aged; D018396:Mucin-1 / Q000097:blood; D009362:Neoplasm Metastasis; D010051:Ovarian Neoplasms / Q000097:blood / Q000175:diagnosis* / Q000473:pathology; D000292:Pelvic Inflammatory Disease / Q000097:blood
D015295:Antigens, Tumor-Associated, Carbohydrate; D019313:BRCA1 Protein; D024682:BRCA2 Protein; D014408:Biomarkers, Tumor; D018394:CA-125 Antigen; D018395:CA-19-9 Antigen; C083825:CA-72-4 antigen; D006023:Glycoproteins; D018396:Mucin-1; C086414:OVX1 antigen; D016173:Macrophage Colony-Stimulating Factor
Ann Oncol. 2008 Apr;19(4):675-81
18037623
Am J Obstet Gynecol. 1991 Nov;165(5 Pt 1):1356-62
1957862
Gynecol Oncol. 1988 May;30(1):7-14
2452773
Gynecol Oncol. 1987 Sep;28(1):61-7
2443433
Cancer Res. 1991 Aug 1;51(15):4012-9
1855217
Obstet Gynecol. 1988 May;71(5):751-6
3162763
J Natl Cancer Inst. 1993 Nov 3;85(21):1748-51
8411259
Cancer. 2001 Dec 1;92(11):2837-44
11753957
Int J Gynecol Cancer. 2005 Nov-Dec;15 Suppl 3:274-81
16343244
Am J Obstet Gynecol. 1988 Aug;159(2):341-6
2457318
Gynecol Oncol. 1992 Feb;44(2):147-54
1312052
Gynecol Oncol. 1999 Apr;73(1):56-61
10094881
Clin Chim Acta. 2006 Sep;371(1-2):112-6
16631152
Tumori. 2006 Nov-Dec;92(6):517-23
17260493
N Engl J Med. 1983 Oct 13;309(15):883-7
6310399
J Clin Oncol. 2004 Oct 15;22(20):4059-66
15381683
Womens Health (Lond). 2009 Nov;5(6):693-9
19863472
Int J Cancer. 1988 Nov 15;42(5):677-80
3182103
N Engl J Med. 2004 Dec 9;351(24):2519-29
15590954
Gynecol Oncol. 2006 Jan;100(1):20-6
16188302
Gynecol Oncol. 2007 Dec;107(3):526-31
17920110
Am J Obstet Gynecol. 1988 Oct;159(4):873-6
3052078